Table 3.
Efficacy Results: Adding Panobinostat versus Placebo to Treatment Regimen in Patients Who Received Previous Bortezomib and Dexamethasone
| Efficacy variables | Panobinostat, bortezomib, dexamethasone (N = 94) | Placebo, bortezomib, dexamethasone (N = 99) |
|---|---|---|
| Progression-free survival | ||
| Median, mo | 10.6 (95% CI, 7.6–13.8) | 5.8 (95% CI, 4.4–7.1) |
| Hazard ratioa | 0.52 (95% CI, 0.36–0.76) | |
a
Hazard ratio obtained from stratified Cox model.
CI indicates confidence interval.
Source: Farydak (panobinostat) capsules prescribing information; February 2015.